Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology
暂无分享,去创建一个
R. Dobson | K. Blennow | J. Molinuevo | P. Scheltens | O. Blin | F. Barkhof | G. Frisoni | H. Soininen | P. Visser | P. Mecocci | B. Vellas | M. Tsolaki | I. Kloszewska | S. Lovestone | K. Sleegers | S. Engelborghs | R. Vandenberghe | A. Morgan | B. Nordestgaard | P. Johannsen | L. Winchester | F. Verhey | A. Cuadrado | L. Frölich | S. F. Nielsen | J. Streffer | A. Franke | S. Kiddle | L. Bertram | R. Bordet | A. Lleó | J. Richardson | H. Zetterberg | A. Wallin | P. Kettunen | Fabian Kilpert | A. Nevado-Holgado | R. Frikke-Schmidt | L. Rami | C. Teunissen | C. Legido-Quigley | M. Sattlecker | A. Hye | S. Westwood | Liu Shi | B. Morgan | Y. Freund-Levi | M. T. Kate | P. Martínez-Lage | N. Buckley | E. Ribe | A. Baird | I. Bos | S. Vos | S. Gabel | J. Popp | V. Dobričić | D. Alcolea | Karen Meersmans | M. Tainta | R. Killick | Shengjun Hong | E. D. De Roeck | N. Ashton | K. Rasmussen | B. Liu | E. D. Roeck | G. Peyratout | M. ten Kate | Abdul Hye | J. Richardson | Lars Bertram | Johannes Streffer | Pieter Jelle Visser | Richard Dobson | Anders Wallin | Petronella Kettunen | V. Dobricic | P. J. Visser
[1] R. Dobson,et al. Genome-wide association study of Alzheimer’s disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset , 2019, bioRxiv.
[2] J. Suckling,et al. Frequency and longitudinal clinical outcomes of Alzheimer's AT(N) biomarker profiles: A longitudinal study , 2019, Alzheimer's & Dementia.
[3] Jiahui Wang,et al. The role of DKK1 in Alzheimer's disease: A potential intervention point of brain damage prevention? , 2019, Pharmacological research.
[4] E. Palomer,et al. Wnt Signaling Deregulation in the Aging and Alzheimer’s Brain , 2019, Front. Cell. Neurosci..
[5] Sterling C. Johnson,et al. ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes , 2019, Neurology.
[6] N. Inestrosa,et al. Loss of canonical Wnt signaling is involved in the pathogenesis of Alzheimer's disease , 2018, Neural regeneration research.
[7] B. Nordestgaard,et al. An updated Alzheimer hypothesis: Complement C3 and risk of Alzheimer's disease—A cohort study of 95,442 individuals , 2018, Alzheimer's & Dementia.
[8] R. Dobson,et al. The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics , 2018, Alzheimer's Research & Therapy.
[9] J. Cummings. The National Institute on Aging—Alzheimer's Association Framework on Alzheimer's disease: Application to clinical trials , 2018, Alzheimer's & Dementia.
[10] C. Jack,et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease , 2018, Alzheimer's & Dementia.
[11] K. Morgan,et al. Complement receptor 1 gene (CR1) intragenic duplication and risk of Alzheimer’s disease , 2018, bioRxiv.
[12] S. Lovestone,et al. Amyloid β synaptotoxicity is Wnt-PCP dependent and blocked by fasudil , 2018, Alzheimer's & Dementia.
[13] R. Marioni,et al. GWAS on family history of Alzheimer’s disease , 2018, bioRxiv.
[14] J. Hardy,et al. Alzheimer's disease , 2018, European journal of neurology.
[15] R. Dobson,et al. A Decade of Blood Biomarkers for Alzheimer’s Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication , 2017, Journal of Alzheimer's disease : JAD.
[16] J. Schott,et al. Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress , 2017, Molecular Diagnosis & Therapy.
[17] Hashem A. Shihab,et al. MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations , 2016, bioRxiv.
[18] F. Cacucci,et al. Reversal of Synapse Degeneration by Restoring Wnt Signaling in the Adult Hippocampus , 2016, Current Biology.
[19] E. Mazzon,et al. The role of the Wnt canonical signaling in neurodegenerative diseases. , 2016, Life sciences.
[20] G. Davey Smith,et al. Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator , 2016, Genetic epidemiology.
[21] S. Lovestone,et al. Blood-Based Proteomic Biomarkers of Alzheimer’s Disease Pathology , 2015, Front. Neurol..
[22] G. Davey Smith,et al. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression , 2015, International journal of epidemiology.
[23] Lennart Thurfjell,et al. Blood protein predictors of brain amyloid for enrichment in clinical trials? , 2015, Alzheimer's & dementia.
[24] M. Pallàs,et al. Downregulation of canonical Wnt signaling in hippocampus of SAMP8 mice , 2015, Neurobiology of Aging.
[25] Jaakko Kopra,et al. Deficient Wnt signalling triggers striatal synaptic degeneration and impaired motor behaviour in adult mice , 2014, Nature Communications.
[26] G. Davey Smith,et al. Mendelian randomization: genetic anchors for causal inference in epidemiological studies , 2014, Human molecular genetics.
[27] N. Inestrosa,et al. In vivo Activation of Wnt Signaling Pathway Enhances Cognitive Function of Adult Mice and Reverses Cognitive Deficits in an Alzheimer's Disease Model , 2014, The Journal of Neuroscience.
[28] N. Inestrosa,et al. Wnt Signaling in the Nervous System and in Alzheimer's Disease Inestrosa and Varela-nallar Inestrosa and Varela-nallar , 2022 .
[29] Nick C Fox,et al. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease , 2013, Nature Genetics.
[30] Andrew D. Johnson,et al. Multiethnic Meta-Analysis of Genome-Wide Association Studies in >100 000 Subjects Identifies 23 Fibrinogen-Associated Loci but No Strong Evidence of a Causal Association Between Circulating Fibrinogen and Cardiovascular Disease , 2013, Circulation.
[31] G. Breen,et al. Clusterin regulates β-amyloid toxicity via Dickkopf-1-driven induction of the wnt–PCP–JNK pathway , 2012, Molecular Psychiatry.
[32] P. Salinas,et al. The Secreted Wnt Antagonist Dickkopf-1 Is Required for Amyloid β-Mediated Synaptic Loss , 2012, The Journal of Neuroscience.
[33] Magda Tsolaki,et al. AddNeuroMed and ADNI: Similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America , 2011, NeuroImage.
[34] Rachel Ostroff,et al. Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery , 2010, PLoS ONE.
[35] Tracy R. Keeney,et al. Aptamer-based multiplexed proteomic technology for biomarker discovery , 2010, PloS one.
[36] Hannah R Rothstein,et al. A basic introduction to fixed‐effect and random‐effects models for meta‐analysis , 2010, Research synthesis methods.
[37] N. Inestrosa,et al. Activation of Wnt signaling by lithium and rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1ΔE9 mouse model of Alzheimer's disease , 2010, Molecular Psychiatry.
[38] G. Terstappen,et al. Increased Dickkopf‐1 expression in transgenic mouse models of neurodegenerative disease , 2010, Journal of neurochemistry.
[39] A. Simmons,et al. AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease , 2009, Annals of the New York Academy of Sciences.
[40] C. Lemere,et al. Complement C3 Deficiency Leads to Accelerated Amyloid β Plaque Deposition and Neurodegeneration and Modulation of the Microglia/Macrophage Phenotype in Amyloid Precursor Protein Transgenic Mice , 2008, The Journal of Neuroscience.
[41] J. Trojanowski,et al. The Alzheimer's Brain , 2005 .
[42] N. Inestrosa,et al. Wnt-3a overcomes β-amyloid toxicity in rat hippocampal neurons , 2004 .
[43] E. Aronica,et al. Induction of Dickkopf-1, a Negative Modulator of the Wnt Pathway, Is Associated with Neuronal Degeneration in Alzheimer's Brain , 2004, The Journal of Neuroscience.
[44] N. Inestrosa,et al. Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by β-amyloid fibrils , 2003, Molecular Psychiatry.
[45] John D Lambris,et al. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[46] S. Lovestone,et al. Does dysregulation of the Notch and wingless/Wnt pathways underlie the pathogenesis of Alzheimer's disease? , 2000, Molecular medicine today.
[47] A. Ziegler,et al. Mendelian Randomization. , 2017, Methods in molecular biology.
[48] Irving E. Vega,et al. Biomarkers for the Early Detection and Progression of Alzheimer’s Disease , 2016, Neurotherapeutics.
[49] D. Selkoe. Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.
[50] N. Inestrosa,et al. Wnt-3a overcomes beta-amyloid toxicity in rat hippocampal neurons. , 2004, Experimental cell research.